Fish oil and the prevention and regression of atherosclerosis.

Abstract:

:Epidemiological studies in the seventies have put forward that dietary rather than genetic factors are responsible for the lower incidence of ischemic heart disease in Greenland Inuit and have generated a large body of both in vitro and in vivo experimental studies, exploring the putative favorable effects of fish (oil) on atherogenesis and its risk factors. The first part of this report reviews the in vivo animal studies, concentrating on the hypercholesterolemic models and the arterialized vein graft model. In the hypercholesterolemic animal studies, the results are inconclusive as the studies reporting a protective effect are matched by the number of studies showing no effect or an adverse effect. The diversity in species, dose of fish oil, duration of study, type of vessel studied and type of fish oil preparation (content of n-3 fatty acids, unesterified n-3 fatty acids, ethylesters or triglycerides) could all contribute. Furthermore, the definitions and criteria used in the literature to evaluate atherogenesis are diverse and it appears that while one parameter is affected, another is not necessarily modified in the same direction, stressing the importance of extending the analysis of the effects on atherogenesis to more than one parameter. We also believe that it is time to reach a consensus as to which animal model mimics most closely a particular human situation. Only in appropriate models, investigating more than one atherosclerosis variable, can the effects of a putative anti-atherogenic drug or diet be verified. In the veno-arterial autograft model, mimicking the patient after coronary bypass grafting, dietary fish oil has been consistently effective in preventing accelerated graft intima proliferation. It could therefore be of interest to evaluate the effects of fish oil on graft patency in patients after coronary bypass surgery after a period of years. The results from studies on restenosis after percutaneous transluminal angioplasty are also reviewed and it is concluded that the two large scale trials, that are currently underway, might reliably answer the question whether fish oil is effective as a non-pharmacological adjuvants in the prevention of restenosis. Lastly, the studies on the effects of fish oil on the regression of experimental atherosclerosis are reviewed. In view of the small number of studies (i.e., four) investigating the effects of fish oil on the regression of atherosclerosis, it is premature to draw any conclusion, and therefore further experimental work is required.

journal_name

Cardiovasc Drugs Ther

authors

Sassen LM,Lamers JM,Verdouw PD

doi

10.1007/BF00877326

subject

Has Abstract

pub_date

1994-04-01 00:00:00

pages

179-91

issue

2

eissn

0920-3206

issn

1573-7241

journal_volume

8

pub_type

杂志文章,评审
  • Treatment of chronic myocardial ischemia: rationale and treatment options.

    abstract::A rational approach to the treatment of chronic myocardial ischemia requires an appreciation of the pathophysiology of coronary artery disease and the treatment options available. Any factor that causes an imbalance between myocardial oxygen supply and demand can provoke ischemia. Myocardial oxygen requirements rise w...

    journal_title:Cardiovascular drugs and therapy

    pub_type: 杂志文章,评审

    doi:10.1023/a:1007782210758

    authors: Cohn PF

    更新日期:1998-10-01 00:00:00

  • Diuretics in the prevention and treatment of congestive heart failure.

    abstract::Diuretics, either as monotherapy or in combination with other drugs in the management of hypertension, have retarded the development of left ventricular hypertrophy and congestive heart failure in many patients. Diuretics also remain one of the most effective therapies in the treatment of congestive heart failure, whe...

    journal_title:Cardiovascular drugs and therapy

    pub_type: 杂志文章,评审

    doi:10.1023/a:1007791814100

    authors: Moser M

    更新日期:1997-05-01 00:00:00

  • Functional antagonism of different angiotensin II type I receptor blockers in human arteries.

    abstract:OBJECTIVES:To evaluate and compare the functional type and the degree of antagonism of the selective angiotensin II type 1 receptor blockers (ARB) losartan, EXP 3174 (the active metabolite of losartan), valsartan and candesartan in human internal mammary arteries. METHODS:Human internal mammary arteries were obtained ...

    journal_title:Cardiovascular drugs and therapy

    pub_type: 杂志文章

    doi:10.1023/a:1021729909456

    authors: Wagenaar LJ,Voors AA,Buikema H,van Buiten A,Lübeck RH,Boonstra PW,van Veldhuisen DJ,van Gilst WH

    更新日期:2002-07-01 00:00:00

  • Older statin initiators in Finland - cardiovascular risk profiles and persistence of use.

    abstract:PURPOSE:The benefits of statin treatment initiated in advanced age are largely unknown; however, good adherence to treatment is essential for beneficial effects to be achieved also when treating older people. This study characterizes older statin initiators, including their cardiovascular risk profiles and morbidity, a...

    journal_title:Cardiovascular drugs and therapy

    pub_type: 杂志文章

    doi:10.1007/s10557-014-6517-x

    authors: Upmeier E,Korhonen MJ,Rikala M,Helin-Salmivaara A,Huupponen R

    更新日期:2014-06-01 00:00:00

  • Intracoronary administration of adenosine triphosphate increases coronary blood flow and attenuates the severity of myocardial ischemic injury in dogs.

    abstract::ATP generates nitric oxide (NO) via activation of P2y receptors, and is degraded to adenosine. This study was undertaken to examine whether ATP causes coronary hyperemic flow via purinoceptors-, NO- and adenosine-dependent mechanisms, and attenuates the severity of contractile and metabolic dysfunction in the ischemic...

    journal_title:Cardiovascular drugs and therapy

    pub_type: 杂志文章

    doi:10.1023/a:1007899822136

    authors: Kitakaze M,Node K,Komamura K,Minamino T,Kosaka H,Kuzuya T,Hori M

    更新日期:1999-09-01 00:00:00

  • Glucose-insulin-potassium (GIK) for acute myocardial infarction: a negative study with a positive value.

    abstract::Glucose-insulin-therapy for acute myocardial infarction (AMI) has had a long history, going back 37 years to the pioneering concepts of Sodi-Pallares. Although a recent meta-analysis of a number of smaller trials has suggested mortality benefit, it is only the South American trial, published in Circulation in 1998, th...

    journal_title:Cardiovascular drugs and therapy

    pub_type: 评论,社论,评审

    doi:10.1023/a:1007757407246

    authors: Apstein CS,Opie LH

    更新日期:1999-05-01 00:00:00

  • Porcine heparin increases postoperative bleeding in cardiopulmonary bypass patients.

    abstract::One hundred thirteen patients undergoing cardiopulmonary bypass were randomly assigned to receive either bovine or porcine heparin. Heparin was infused at 4.5 mg/kg during bypass and administered at the lesser of 70 units/kg or 5000 units/dose at 12-hour intervals postoperatively. Platelet counts decreased to 45% of p...

    journal_title:Cardiovascular drugs and therapy

    pub_type: 临床试验,杂志文章,随机对照试验

    doi:10.1007/BF01857644

    authors: Iverson LI,Duhaylongsod FG,Young JN,Ecker RR,Ennix CL Jr,Moretti RL,Farrar M,Hayes R,Lee J,May IA

    更新日期:1990-02-01 00:00:00

  • Drug interactions with colesevelam hydrochloride, a novel, potent lipid-lowering agent.

    abstract::Colesevelam hydrochloride (colesevelam) is a novel, potent, bile acid-binding agent that has been shown to lower LDL cholesterol a mean of 19% at a dose of 3.8 g/d. We studied the pharmacokinetics of colesevelam coadministered with six drugs: digoxin and warfarin, agents with narrow therapeutic indices; sustained-rele...

    journal_title:Cardiovascular drugs and therapy

    pub_type: 临床试验,杂志文章

    doi:10.1023/a:1007831418308

    authors: Donovan JM,Stypinski D,Stiles MR,Olson TA,Burke SK

    更新日期:2000-12-01 00:00:00

  • Regulation of arterial tone by calcium-dependent K+ channels and ATP-sensitive K+ channels.

    abstract::Resistance arteries depolarize and constrict to elevations in intravascular pressure. However, many of the molecular aspects of this phenomenon are not known. We present evidence that large conductance calcium-dependent potassium (KCa) channels, which are activated by intracellular calcium and membrane depolarization,...

    journal_title:Cardiovascular drugs and therapy

    pub_type: 杂志文章,评审

    doi:10.1007/BF00877627

    authors: Nelson MT,Brayden JE

    更新日期:1993-08-01 00:00:00

  • Calcium antagonists and myocardial infarction.

    abstract::In vitro and in vivo studies have demonstrated many similarities between the three calcium antagonists verapamil, nifedipine, and diltiazem in relation to protection of the myocardium during hypoxia. Important clinical differences exist between the three drugs when they are used during or after an acute myocardial inf...

    journal_title:Cardiovascular drugs and therapy

    pub_type: 杂志文章,评审

    doi:10.1007/BF03029738

    authors: Hansen JF

    更新日期:1991-08-01 00:00:00

  • The Association of Low Molecular Weight Heparin Use and In-hospital Mortality Among Patients Hospitalized with COVID-19.

    abstract:PURPOSE:To determine the association between low molecular weight heparin (LMWH) use and mortality in hospitalized COVID-19 patients. METHODS:We conducted a retrospective study of patients consecutively enrolled from two major academic hospitals exclusively for COVID-19 in Wuhan, China, from January 26, 2020, to March...

    journal_title:Cardiovascular drugs and therapy

    pub_type: 杂志文章

    doi:10.1007/s10557-020-07133-3

    authors: Shen L,Qiu L,Liu D,Wang L,Huang H,Ge H,Xiao Y,Liu Y,Jin J,Liu X,Wang DW,Peterson ED,He B,Zhou N

    更新日期:2021-01-04 00:00:00

  • The initial hemodynamic response to newer antihypertensive agents at rest and during exercise: review of visacor, doxazosin, nisoldipine, tiapamil, perindoprilat, pinacidil, dilevalol, and carvedilol.

    abstract::Antihypertensive drugs may lower blood pressure through very different mechanisms, initially as well as during chronic use. This article is a review of the immediate hemodynamic changes induced by a beta blocker (visacor), an alpha-receptor blocker (doxazosin), two calcium antagonists (tiapamil and nisoldipine), an an...

    journal_title:Cardiovascular drugs and therapy

    pub_type: 杂志文章

    doi:10.1007/BF01856510

    authors: Omvik P,Lund-Johansen P

    更新日期:1990-08-01 00:00:00

  • A multicenter study of a new inotropic agent, piperanometozine (OPC-8212) in congestive heart failure: clinical improvement during short-term treatment.

    abstract::Piperanometozine (OPC-8212) is a new, orally effective inotropic agent. To evaluate the efficacy of this agent on systemic hemodynamics and clinical symptoms in patients with congestive heart failure, a multicenter study was performed. Thirty four patients with New York Heart Association (NYHA) functional classes II t...

    journal_title:Cardiovascular drugs and therapy

    pub_type: 临床试验,杂志文章,多中心研究

    doi:10.1007/BF02125470

    authors: Inoue M,Hori M,Yasuda H,Takishima T,Sugimoto T,Sasayama S,Sakurai T,Nonogi H,Kodama K,Kusukawa R

    更新日期:1987-08-01 00:00:00

  • The problem of defining heart failure.

    abstract::A succession of theories arising from last century has attempted to explain why patients with damaged hearts develop peripheral edema. Opposed to the original simple concepts of backward failure, a number of theories of forward failure have been proposed, the cardiac output being considered inadequate for capillary pe...

    journal_title:Cardiovascular drugs and therapy

    pub_type: 杂志文章,评审

    doi:10.1007/BF00877921

    authors: Harris P

    更新日期:1994-06-01 00:00:00

  • Torsades de pointes: arrhythmia, syndrome, or chimera?

    abstract::Although torsades de pointes is not a tightly demarcated entity, the diagnosis has important clinical implications. The concept should be retained. ...

    journal_title:Cardiovascular drugs and therapy

    pub_type: 杂志文章

    doi:10.1007/BF03029821

    authors: Millar RN

    更新日期:1991-02-01 00:00:00

  • When is discontinuation of antihypertensive therapy indicated?

    abstract::Major advances have been established in the handling of hypertensive vascular disease in recent years. However, drug compliance, drug costs, and the side effects of antihypertensive agents have prompted the question of whether intermittent therapy or even possible removal of medication represents an alternative to lif...

    journal_title:Cardiovascular drugs and therapy

    pub_type: 杂志文章,评审

    doi:10.1007/BF02026496

    authors: Schmieder RE,Rockstroh JK

    更新日期:1990-12-01 00:00:00

  • A systemic combination therapy with granulocyte-colony stimulating factor plus erythropoietin aggravates the healing process of balloon-injured rat carotid arteries.

    abstract:OBJECTIVE:Percutaneous vascular interventions lead inevitably to a destruction of the endothelial lining at the site of injury. There are conflicting data on the therapeutic benefit of hematopoietic growth factors aiming at mobilisation of circulating endothelial cells to accelerate the reendothelialisation process. Ai...

    journal_title:Cardiovascular drugs and therapy

    pub_type: 杂志文章

    doi:10.1007/s10557-008-6117-8

    authors: Hack M,Mascha FG,Jobst BJ,Riegger GA,Griese DP

    更新日期:2008-10-01 00:00:00

  • Anti-arrhythmic effects of I (Na), I (Kr), and combined I (Kr)-I (CaL) blockade in an experimental model of acute stretch-related atrial fibrillation.

    abstract:INTRODUCTION:Atrial dilatation is commonly associated with atrial fibrillation (AF), but the electrophysiological mechanisms and the implications for anti-arrhythmic therapy are poorly understood. In a model of acute stretch-related AF in isolated rabbit hearts, we evaluated the electrophysiological effects of three di...

    journal_title:Cardiovascular drugs and therapy

    pub_type: 杂志文章

    doi:10.1007/s10557-007-6001-y

    authors: Kalifa J,Bernard M,Gout B,Bril A,Cozma D,Laurent P,Chalvidan T,Deharo JC,Djiane P,Cozzone P,Maixent JM

    更新日期:2007-02-01 00:00:00

  • Safety, tolerability, and neurohormonal changes of the combination captopril plus losartan in the early postinfarction period: a pilot study.

    abstract::Suppression of formation of angiotensin II (A-II) is thought to be a major contributor to the hemodynamic response to angiotensin-converting enzyme inhibition (ACE-in) therapy. However, angiotensin II (A-II) plasma levels may rebound during ACE-in treatment. The study sought to verify the feasibility, safety, and tole...

    journal_title:Cardiovascular drugs and therapy

    pub_type: 临床试验,杂志文章,随机对照试验

    doi:10.1023/a:1007739412802

    authors: Di Pasquale P,Bucca V,Scalzo S,Paterna S

    更新日期:1998-05-01 00:00:00

  • Correction to: Do Limitations in the Design of PARADIGM-HF Justify the Slow Real World Uptake of Sacubitril/Valsartan (Entresto)?

    abstract::The original version of this article unfortunately contained a mistake. There was a typo in the second sentence of the paragraph under the section Was the Dose of Drugs Fair?; "320 mg twice a day" should read "160mg twice a day". The corrected paragraph is shown below. ...

    journal_title:Cardiovascular drugs and therapy

    pub_type: 杂志文章,已发布勘误

    doi:10.1007/s10557-018-6834-6

    authors: Ahn R,Prasad V

    更新日期:2018-12-01 00:00:00

  • Influence of the new class I antiarrhythmic agent diprafenone on the end-systolic pressure-volume relationship (conductance technique).

    abstract::To evaluate cordiodepressive risks of antiarrhythmic treatment with diprafenone, we monitored, in addition to conventional hemodynamic parameters, end-systolic pressure-volume relations to assess potential negative inotropic effects. Thirteen patients underwent hemodynamic analysis with and without the influence of di...

    journal_title:Cardiovascular drugs and therapy

    pub_type: 杂志文章

    doi:10.1007/BF01883858

    authors: Thormann J,Kramer W,Kremer P,Schlepper M

    更新日期:1989-04-01 00:00:00

  • Hemodynamic and antiischemic effects of intravenous elgodipine, a new dihydropyridine calcium channel blocker, in patients with chronic stable angina.

    abstract::Elgodipine is a new second-generation dihydropyridine calcium antagonist. Its hemodynamic and antiischemic properties were evaluated in a single-blind, placebo-controlled trial in 22 males with chronic stable angina. Coronary artery disease was angiographically confirmed. Measurements were performed with a Swan-Ganz t...

    journal_title:Cardiovascular drugs and therapy

    pub_type: 临床试验,杂志文章

    doi:10.1007/BF00878092

    authors: Kuhn A,Carlsson J,Miketic S,Tebbe U

    更新日期:1995-08-01 00:00:00

  • Comparison of the effectiveness of dihydroquinidine and quinidine on ventricular ectopy after acute and chronic administration.

    abstract::The aim of this study was to compare the pharmacokinetics and antiarrhythmic activity of dihydroquinidine and quinidine in 14 patients (11 men, 3 women, aged 28 to 67 years) with heart disease and chronic, stable, high-frequency premature ventricular beats (PVB) (greater than 100/hr). A randomized, double-blind, cross...

    journal_title:Cardiovascular drugs and therapy

    pub_type: 临床试验,杂志文章,随机对照试验

    doi:10.1007/BF00054209

    authors: Chimienti M,Regazzi MB,La Rovere MT,Salerno JA,Previtali M,Montericcio V,Rondanelli R,Montemartini C

    更新日期:1988-12-01 00:00:00

  • Study Design and Rationale of "A Multicenter, Open-Labeled, Randomized Controlled Trial Comparing MIdazolam Versus MOrphine in Acute Pulmonary Edema": MIMO Trial.

    abstract:PURPOSE:Morphine has been used for several decades in cases of acute pulmonary edema (APE) due to the anxiolytic and vasodilatory properties of the drug. The non-specific depression of the central nervous system is probably the most significant factor for the changes in hemodynamics in APE. Retrospective studies have s...

    journal_title:Cardiovascular drugs and therapy

    pub_type: 杂志文章,多中心研究,随机对照试验

    doi:10.1007/s10557-017-6722-5

    authors: Dominguez-Rodriguez A,Burillo-Putze G,Garcia-Saiz MDM,Aldea-Perona A,Harmand MG,Mirò O,Abreu-Gonzalez P,MIMO investigators.

    更新日期:2017-04-01 00:00:00

  • Asialoerythropoietin exerts stronger angiogenic activity than erythropoietin via its binding affinity to tissue.

    abstract:PURPOSE:Although erythropoietin (EPO) is known to express angiogenic and cardioprotective effects, it also induces hypertension, polycythemia, and platelet activation, which may cause serious adverse effects in patients with cardiovascular diseases. We compared the angiogenic effects of EPO and its nonerythropoietic de...

    journal_title:Cardiovascular drugs and therapy

    pub_type: 杂志文章

    doi:10.1007/s10557-013-6438-0

    authors: Yanagawa T,Toba K,Kato K,Suzuki T,Minagawa S,Saigawa T,Ozawa T,Oda M,Takayama T,Hanawa H,Higuchi M,Saito H,Aizawa Y

    更新日期:2013-04-01 00:00:00

  • Combination Therapy of Pulmonary Arterial Hypertension with Vardenafil and Macitentan Assessed in a Human Ex Vivo Model.

    abstract:PURPOSE:Treatment of pulmonary arterial hypertension (PAH) by vasodilator drug monotherapy is often limited in its effectiveness. Combination therapy may help to improve treatment and to reduce drug toxicity. This study assessed the combination of the endothelin receptor antagonist macitentan and the phosphodiesterase-...

    journal_title:Cardiovascular drugs and therapy

    pub_type: 杂志文章

    doi:10.1007/s10557-019-06868-y

    authors: Hoenicka M,Golovchenko S,Englert L,Spaeth M,Shoshiashvili L,Großer C,Hofmann HS,Ried M

    更新日期:2019-06-01 00:00:00

  • Inhibition of the cerebral renin-angiotensin system to limit cognitive decline in elderly hypertensive persons.

    abstract::Inhibition of then renin-angiotensin system (RAS) ranks among the best established and most used cardiovascular therapies. By providing protection against hypertension and heart failure, and also the microvascular complications of diabetes, RAS inhibitors have contributed to the longer life-expectancy now found in hig...

    journal_title:Cardiovascular drugs and therapy

    pub_type: 社论

    doi:10.1007/s10557-011-6316-6

    authors: Opie LH

    更新日期:2011-08-01 00:00:00

  • Pharmacotherapy of dyslipidemia.

    abstract::Reducing elevated levels of low-density-lipoprotein cholesterol (LDL-C) significantly reduces the incidence of coronary heart disease (CHD) events and mortality in hypercholesterolemic patients. CHD risk reduction is proportional to LDL-C reduction. Despite this knowledge, many physicians are not applying existing tre...

    journal_title:Cardiovascular drugs and therapy

    pub_type: 杂志文章,评审

    doi:10.1023/a:1013341606476

    authors: McKenney JM

    更新日期:2001-09-01 00:00:00

  • Lisinopril in the treatment of congestive heart failure in elderly patients: comparison versus captopril.

    abstract::The present study was performed in order to compare the efficacy, safety, and tolerability of lisinopril, a long-acting angiotensin-converting enzyme (ACE) inhibitor, with captopril, the shorter acting ACE inhibitor available, in the treatment of elderly patients (mean age 70 +/- 0.5 years) with congestive heart failu...

    journal_title:Cardiovascular drugs and therapy

    pub_type: 临床试验,杂志文章,多中心研究,随机对照试验

    doi:10.1023/a:1007704024393

    authors: Morisco C,Condorelli M,Crepaldi G,Rizzon P,Zardini P,Villa G,Argenziano L,Trimarco B

    更新日期:1997-03-01 00:00:00

  • Sympathetic nervous system in salt-sensitive and obese hypertension: amelioration of multiple abnormalities by a central sympatholytic agent.

    abstract::Excess activity of the sympathetic nervous system (SNS) is linked to human obese hypertension and to salt-sensitive hypertension. Paradoxically, reduced SNS activity has been implicated as a contributor to obesity, particularly in animal models, and salt loading usually inhibits SNS activity. We have investigated the ...

    journal_title:Cardiovascular drugs and therapy

    pub_type: 杂志文章

    doi:10.1007/BF00120497

    authors: Ernsberger P,Koletsky RJ,Collins LA,Bedol D

    更新日期:1996-06-01 00:00:00